What happened with MBOT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Microbot Medical’s sole product, LIBERTY, lets physicians remotely move guidewires and catheters inside blood vessels during interventional procedures. The robot is fully disposable, and the company intends to focus on peripheral blood vessels. It shifted its main focus from research and development to commercialization in 2025.
Healthcare institutions are the intended buyers. Their willingness to purchase depends partly on whether insurers and other healthcare payors adequately reimburse procedures using the device; otherwise, institutions must absorb its cost within the procedure payment. Microbot had earned no revenue through the end of 2025 and had mainly funded operations through share offerings and grants. Turning LIBERTY into a revenue-producing business depends on physician acceptance, third-party manufacturing, sales and distribution capabilities, and additional funding.
LIBERTY has U.S. regulatory clearance, but European CE marking and an Israeli medical-device license remained pending at the filing date. Authorization in one country does not permit sales in another. Israeli government development grants also restrict moving grant-supported technology or manufacturing outside Israel without prior approval from the Israel Innovation Authority.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
With no revenue through 2025, Microbot Medical depends chiefly on developing LIBERTY successfully and winning clinical adoption, rather than on established vascular-device makers’ current sales trends.
Merit Medical Systems sells microcatheters, vascular-access devices and peripheral-intervention products for the procedures Microbot Medical aims to support with LIBERTY’s robotic handling of guidewires and catheters. Merit’s peripheral-intervention sales offer a read on demand for those procedures, not on adoption of Microbot’s robot.
Boston Scientific sells peripheral-intervention devices into the treatment market Microbot Medical targets with its robot for manipulating guidewires and catheters. Watch news about those devices for a view of that market; Boston Scientific folded Peripheral Interventions into its broader Cardiovascular business in the fourth quarter of 2025.
Merit Medical Systems Inc earningsMMSI
Merit Medical Systems’ report will show how sales of its peripheral-intervention products are doing, offering a read on demand for the procedures Microbot Medical aims to support.
Look at changes in Merit Medical Systems’ peripheral-intervention sales. Growth would point to demand for the procedures Microbot Medical targets providing a more supportive market; weakness would suggest a tougher demand backdrop. Neither outcome shows whether hospitals will adopt Microbot Medical’s robot.
Microbot Medical, Inc. earningsThis company
Microbot Medical’s report will show whether LIBERTY commercialization is beginning to bring in sales, and what it is costing the company to pursue them.
Read revenue alongside operating expenses and cash used in operations. Revenue appearing without expenses and cash use rising faster would show commercialization beginning to turn investment into sales. No revenue with continued spending would mean Microbot is still funding commercialization without sales to support the business.
